Nasdaq:DXCM
DEXCOM INC
DEXCOM Inc. is a leading provider of continuous glucose monitoring systems that deliver real-time blood sugar data to millions of people with diabetes globally.
Key Metrics
Investment Thesis
Bull Case
As a dominant player in the high-growth diabetes technology sector, DEXCOM is well-positioned to capture increasing market share as global diabetes prevalence rises and payers expand coverage for continuous monitoring. The company's consistent revenue expansion and improving profitability margins suggest that its technological moat will withstand competitive pressures from lower-cost alternatives. Strong cash generation from operations of $1.44B provides ample flexibility for R&D investments and shareholder returns through dividends or buybacks.
Bear Case
Valuation multiples may appear stretched relative to historical averages given the high growth rate, leaving little margin of safety if macroeconomic headwinds slow consumer spending on elective medical devices. Potential regulatory hurdles in new geographic markets could delay international expansion plans that are critical for sustaining long-term revenue compounding. Dependence on a single primary product line with a short lifecycle (typically 12-24 months per sensor) creates inherent cyclicality and inventory obsolescence risks.
About DEXCOM INC
DEXCOM Inc. designs, manufactures, and markets continuous glucose monitoring (CGM) systems that provide real-time data to patients with diabetes, healthcare professionals, and caregivers. Operating primarily in the United States, Europe, and Asia, the company's key products include the Dexcom G6 and G7 CGM sensors, which transmit glucose readings via Bluetooth to compatible mobile devices. The firm serves a diverse market encompassing insulin-treated adults, pediatric patients, and individuals managing diabetes through continuous monitoring.
Analysis
Management Discussion
Revenue growth of approximately 15% year-over-year to $4.66B reflects strong demand for CGM systems as reimbursement rates improve and patient adoption accelerates. Net income surged by 45% to $836.3M, driven by operational leverage from scaling manufacturing volumes and favorable foreign exchange impacts on cash flows. The company successfully balanced aggressive capital expenditures of $363.5M against substantial share repurchases of $500M, signaling confidence in its long-term growth trajectory.
Industry Overview
The continuous glucose monitoring industry is experiencing rapid evolution as insurers and government programs increasingly mandate coverage for CGM devices to improve diabetes outcomes. Technological advancements in wireless connectivity and AI-driven analytics are transforming raw data streams into actionable insights that empower patients to manage their condition more effectively. Consolidation is expected as larger medical device firms acquire niche players or develop their own proprietary sensor technologies to compete for the lucrative diabetic care market.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $2.91B | $3.62B | $4.03B | $4.66B |
| Cost of Revenue | $1.03B | $1.33B | $1.59B | $1.86B |
| Gross Profit | $1.88B | $2.29B | $2.44B | $2.80B |
| Operating Expenses | $1.49B | $1.69B | $1.84B | $1.89B |
| Operating Income | $391.2M | $597.7M | $600.0M | $911.8M |
| R&D | $484.2M | $505.8M | $552.4M | $599.1M |
| G&A | $1.00B | $1.19B | $1.29B | $1.29B |
| Stock-Based Comp | $126.5M | $150.8M | $170.4M | $159.6M |
| D&A | $155.9M | $186.0M | $217.7M | $251.8M |
| Depreciation | $144.1M | $147.4M | $181.2M | $219.0M |
| Amortization | $7.5M | $8.1M | $6.7M | $4.2M |
| Other OpEx | $7.5M | $0 | $0 | $0 |
| Non-Operating Income | $-400.0K | $112.7M | $109.0M | $176.6M |
| Interest Expense | $18.6M | $20.3M | — | — |
| Pre-Tax Income | $390.8M | $710.4M | $709.0M | $1.09B |
| Income Tax | $49.6M | $168.9M | $132.8M | $252.1M |
| Continuing Ops | $341.2M | $541.5M | $576.2M | $836.3M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $341.2M | $541.5M | $576.2M | $836.3M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $341.2M | $541.5M | $576.2M | $836.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $3.67B | $4.43B | $4.30B | $4.03B |
| Cash & Equivalents | $642.3M | $566.3M | $606.1M | $917.7M |
| Accounts Receivable | $713.3M | $973.9M | $1.01B | $1.22B |
| Inventory | $306.7M | $559.6M | $542.6M | $629.1M |
| Prepaid Expenses | $192.6M | $168.3M | $173.7M | $189.4M |
| Other Current Assets | $1.81B | $2.16B | $1.97B | $1.08B |
| Long-Term Assets | $1.72B | $1.84B | $2.18B | $2.31B |
| Intangibles | $173.3M | $134.5M | $103.4M | $70.8M |
| Goodwill | $25.7M | $25.2M | $22.8M | $24.2M |
| Operating Leases | $80.0M | $71.4M | $62.8M | $77.4M |
| LT Investments | — | $38.5M | $119.3M | $218.0M |
| Other LT Assets | $1.44B | $1.57B | $1.87B | $1.92B |
| Total Assets | $5.39B | $6.26B | $6.48B | $6.34B |
| Current Liabilities | $1.84B | $1.56B | $2.93B | $2.14B |
| Current Leases | $20.5M | $21.1M | $22.5M | $21.6M |
| Deferred Revenue | $10.1M | $18.4M | $8.0M | — |
| Taxes Payable | — | $7.5M | $3.9M | $8.9M |
| Other Current Liab | $1.81B | $1.51B | $2.90B | $2.11B |
| Long-Term Liabilities | $1.42B | $2.64B | $1.45B | $1.45B |
| LT Operating Leases | $94.6M | $80.1M | $65.0M | $73.4M |
| Other LT Liab | $1.31B | $2.55B | $1.38B | $1.33B |
| Total Liabilities | $3.26B | $4.20B | $4.38B | $3.59B |
| Shareholders' Equity | $2.13B | $2.07B | $2.10B | $2.75B |
| Retained Earnings | $479.9M | $1.02B | $1.60B | $2.43B |
| AOCI | $-11.6M | $-16.7M | $-8.0M | $115.0M |
| Total L&E | $5.39B | $6.26B | $6.48B | $6.34B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $341.2M | $541.5M | $576.2M | $836.3M |
| Non-Cash Adjustments | $-268.6M | $-787.5M | $241.2M | $-66.9M |
| Working Capital Changes | $596.9M | $994.5M | $172.1M | $671.3M |
| Cash from Operations | $669.5M | $748.5M | $989.5M | $1.44B |
| Capital Expenditures | $364.8M | $236.6M | $358.8M | $363.5M |
| Cash from Investing | $-521.5M | $-507.2M | $-207.5M | $536.0M |
| Share Buybacks | $557.7M | $688.7M | $750.0M | $500.0M |
| Cash from Financing | $-552.5M | $-318.6M | $-734.8M | $-1.69B |
| FX Effect | $-5.8M | $1.5M | $-7.4M | $21.5M |
| Net Change in Cash | $-410.3M | $-75.8M | $39.8M | $311.8M |
| Beginning Cash | $1.05B | $643.3M | $567.5M | $607.3M |
| Ending Cash | $643.3M | $567.5M | $607.3M | $919.1M |
Frequently Asked Questions
How does DEXCOM INC make money?
The company's revenue is driven by the sale of its proprietary CGM sensors and receiver units, which are sold directly to patients and through healthcare professionals. A significant portion of operating expenses relates to research and development efforts focused on sensor accuracy, wear time, and integration with digital health ecosystems. Additionally, the business leverages strategic partnerships with major pharmaceutical companies and payers to expand market access and reimbursement coverage.
What are the main risks for DXCM?
Regulatory scrutiny and potential changes in reimbursement policies from major payers could materially impact the addressable market and profit margins for CGM devices. Intense competition from emerging players like Abbott and Medtronic, as well as low-cost generic sensor entrants, poses a threat to market share and pricing power. Supply chain disruptions affecting critical semiconductor components or raw materials could lead to production delays that erode customer trust and sales momentum.
What is DXCM's competitive advantage?
DEXCOM maintains a robust first-mover advantage in the CGM space with over two decades of product iteration, resulting in superior sensor accuracy and longer wear times compared to legacy competitors. The company benefits from strong brand recognition and an extensive network of authorized distributors that ensure high market penetration across both developed and emerging markets. Proprietary algorithms and seamless mobile app integration create a sticky ecosystem for users who rely on continuous data streams for insulin dosing decisions.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.